NCT01723904View on ClinicalTrials.gov

A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

April 30, 2013

Conditions
Advanced Parkinson's Disease
Interventions
DRUG

Rotigotine

Application of Rotigotine up to 8 mg/24 h patches for 24 hours.

Trial Locations (22)

Unknown

402, Chatswood

401, Sydney

403, Melbourne

202, Kuala Terengganu

204, Kuching Sarawak

201, Pulau Pinang

501, Singapore

502, Singapore

104, Busan

112, Busan

109, Daegu

111, Gyeonggi-do

101, Seoul

102, Seoul

103, Seoul

105, Seoul

107, Seoul

108, Seoul

110, Seoul

302, Taichung

303, Tainan City

306, Taipei

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

UCB BIOSCIENCES GmbH

INDUSTRY